Bio-Gene Reports $1.4m Loss, Raises A$2.46m, and Secures Key Regulatory Approval

Progress in Bio-Insecticide Development

Bio-Gene Technology Limited (ASX: BGT) has delivered a robust update for the half-year ended 31 December 2025, highlighting key milestones in the advancement of its novel bio-insecticides Flavocide and Qcide. The company’s focus on nature-derived pest control solutions is gaining traction, underscored by the recent approval of Qcide by the US Organic Materials Review Institute (OMRI) for use as a botanical pesticide under the USDA National Organic Program. This endorsement opens doors to organic agriculture markets and eco-conscious consumer products.

Meanwhile, Flavocide demonstrated compelling efficacy in independent research conducted by Purdue University, showing over 90% mortality of deer tick nymphs, the vector for Lyme disease, within 24 hours and sustained residual activity for up to four weeks. This validation supports Bio-Gene’s ongoing formulation development and regulatory submission efforts.

Strategic Partnerships and Funding

Bio-Gene has broadened its commercial and research partnerships internationally, engaging stakeholders in Singapore, India, and Japan. The company also secured two development grants totaling A$3 million from the US Department of Defense’s Deployed Warfighter Protection Program, aimed at advancing wearable mosquito protection devices and indoor residual sprays targeting pests such as bed bugs and houseflies.

Capital raising efforts have been productive, with the company completing placements and a Share Purchase Plan that raised a combined A$2.46 million before costs. This funding supports ongoing research, regulatory studies, and commercialisation initiatives, although Bio-Gene reported a net loss of approximately A$1.4 million for the period, reflecting continued investment in R&D and product development.

Financial Position and Outlook

Despite the loss, Bio-Gene maintains a cash balance of just over A$1 million at the end of December 2025. The directors acknowledge a material uncertainty regarding the company’s ability to continue as a going concern, contingent on successful future capital raises. However, management remains confident, citing positive cash flow forecasts and a strong track record of accessing capital.

Looking ahead, Bio-Gene has initiated critical toxicology studies for Flavocide, including reproductive and neurotoxicity assessments, with preliminary data expected later this year. These studies are pivotal for regulatory submissions to authorities such as the Australian Pesticides and Veterinary Medicines Authority (APVMA) and international regulators.

Operationally, the company continues to optimise Qcide production processes in Far North Queensland and explore new product applications with shorter market entry timelines. The appointment of a new Chief Financial Officer, Drew Speedy, signals a strengthening of Bio-Gene’s leadership team as it navigates the next phase of growth.